Table 1 Main clinical features of patients with transformed mycosis fungoides, SS and cutaneous anaplastic large cell lymphoma, and prevalence of CDKN2A/CDKN2B genetic loss
From: CDKN2A–CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma
Diagnosis | Number of patients | Sex ratio M:F | Age (mean) | TNM stage | Tissue origin | Number of cases with CDKN2A/CDKN2B genetic loss |
|---|---|---|---|---|---|---|
Transformed mycosis fungoides | 24 | 18:7 | 41–86 years (69 years) | IIb (T3): n=17 IVa (T4/T3): n=1 IVb (T3): n=3 NA: n=3 | Skin: n=24 Blood: n=3 Node: n=1 Spleen: n=1 (Total n=29) | 17 (71%) |
Sézary syndrome | 16 | 10:6 | IIIb (T4): n=2 IVa1 (T4): n=10 IVa2 (T4): n=4 | Blood: n=16 (Total n=16) | 7 (44%) | |
CD30+ cutaneous anaplastic large cell lymphoma | 18 | 11:8 | 12–85 years (56 years) | T1a: n=7 T1b: n=1 T2a: n=1 T2b: n=1 T3b: n=2 T3c: n=1 NA n=5 | Skin: n=18 Blood: n=2 Node: n=2 (Total n= 22) | 1 (6%) |
